Tag: bluebird bio Inc (BLUE)

bluebird bio Receives Approval for its Gene Therapy SKYSONA™ for Young People with Early CALD Without a Matched Sibling Donor

bluebird bio Receives EC Approval for  bluebird bio (BLUE) announced that the European Commission (EC) has granted marketing authorization of SKYSONA™ (elivaldogene autotemcel, Lenti-D™) one-time gene therapy for the treatment of early cerebral adrenoleukodystrophy (CALD) in patients less than 18 years of age with an ABCD1 genetic mutation, and for whom a human leukocyte antigen . . . This content is for paid subscribers. Please click here to subscribe or here to …

Important News and Results from Two Companies in the Prohost Portfolio

Important News and Results from Akero Therapeutics Akero Therapeutics (AKRO) announced that full results of the main portion of its Phase 2a BALANCED trial in biopsy-confirmed NASH patients with F1-F3 fibrosis have been published in Nature Medicine. The study shows investigational NASH Drug Efruxifermin (EFX) reduced liver fat to normal levels and reversed fibrosis after 16 weeks . . . This content is for paid subscribers. …

Your Questions, Our Answers

Prohost Portfolio PLUS (formerly The Week in Review) Your Questions, Our Answers In the upcoming issues of Prohost Portfolio PLUS, as with all our Tables, we will include observations and target changes as well as any current news we feel is important enough to be reviewed and/or discussed. We hope you will visit us weekly for updates. Included in this Issue are the Following: Anixa …

bluebird bio Temporarily Suspends Studies of LentiGlobin Gene Therapy for SCD. See Also: Cellectis is Outperforming

bluebird bio Suspends LentiGlobin Studies bluebird bio (BLUE) placed its Phase 1/2 (HGB-206) and Phase 3 (HGB-210) studies of LentiGlobin gene therapy for sickle cell disease (SCD), bb1111, on a temporary suspension due to a reported Suspected Unexpected Serious Adverse Reaction (SUSAR) of acute myeloid leukemia (AML . . . This content is for paid subscribers. Please click here to subscribe or here to log in.

bluebird bio: The Appealing Decision to Separate its Severe Genetic Disease and Oncology Businesses into Independent Publicly-Traded Firms

bluebird bio Decision to Separate its Businesses bluebird bio (BLUE) will retain focus on its severe genetic disease (SGD) and will launch its oncology business (Oncology Newco) as a new entity. The Board of Directors at bluebird bio approved this decision and it is anticipated that the spin-out of Oncology Newco is to be tax-free . . . This content is for paid subscribers. Please click here to …

The Biotechnology Industry

Prohost Letter #443 The Biotechnology Industry The Biotechnology Industry revolutionized the arts of life sciences with accomplishments promising a tremendous improvement in the treatment of chronic, debilitating, progressive and life-threatening diseases. The improved approaches have been game changers in the treatment of cancers and genetic-derived hereditary and non-hereditary chronic diseases. The out-performance was made possible through the biotech industry’s creativity, innovation and remarkable productivity. The …

About bluebird bio

bluebird bio bluebird bio (BLUE) financial results and business highlights for the third quarter 2020 are important to be aware of when volatility and negative analysis lack common sense. The stock selloff has been steady and progressive while there was no bad news emanating from the clinical trials on gene therapy that would provide cures or from any FDA . . . This content is …
Let the Market Plummet But Not Our stocks

Let the Market Plummet But Not Our stocks

The Market May be Plummeting But Prohost Picks are Not Biotech stocks had a strong start, but the gains disappeared in many stocks as the market demonstrated bearishness following a long-lasting rally. Currently, during the strong economic conditions, commentators attribute the reasons for the market’s upside and downside moves to China’s positive, or negative ongoing negotiations rather than to fair correction of overbought or oversold …
RegenxBio is Rebounding. See Also: A Scientifically Valuable Agreement Between CRISPR Therapeutics and KSQ Therapeutics

RegenxBio is Rebounding. See Also: A Scientifically Valuable Agreement Between CRISPR Therapeutics and KSQ Therapeutics

RegenxBio Rebounding RegenxBio (RGNX) has the viral vectors which could safely deliver genes into the cells. The firm has improved the adeno-associated viruses making them safe and effective gene delivery vehicles. One of the three currently approved gene therapy products, Zolgensma® for pediatric spinal muscular atrophy (SMA), marketed by Novartis, used RegenxBio’s adeno-associated . . . This content is for paid subscribers. Please click here to …
What Are We Experiencing Now?

What Are We Experiencing Now?

Prohost Letter #436 What Are We Experiencing Now? The bizarre market underperformance progressing rather than regressing and the good economy and the employment gains are the least utilized factors after being the most influential on the stock market performance. We are witnessing the most bullish analysts being confused, hesitating to give their followers a crystal clear explanation about the market’s skepticism, anger and volatility. The …
The Value of the Biotech Companies Continued

The Value of the Biotech Companies Continued

Prohost Letter #435 The Value of the Biotech Companies A Continuation of Prohost Letter #434 A Recap The biotech near and long-term values, we insist, must be based on the firms’ scientific capabilities, products’ potentials and financial results. In the past months the stocks evaluations by bloggers, and some assessors, have been tailored to mislead investors into serving the purposes of the manipulators’ weird agendas. …
At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

At bluebird bio an Investigational Gene Therapy is Demonstrating Promising Results

bluebird bio Has Promising Results from Its Lenti-D Gene Therapy for CALD Good results have come from bluebird bio’s (BLUE) updated results in the clinical development program for its investigational Lenti-D™ gene therapy in patients with cerebral adrenoleukodystrophy (CALD) at the 13th European Pediatric Neurology Society (EPNS) Congress in Athens, Greece. bluebird bio's Starbeam Trial . . . This content is for paid subscribers. Please click here to subscribe or here to …
About RegenxBio’s Agreement with Clearside Biomedical and More

About RegenxBio’s Agreement with Clearside Biomedical and More

Diseases of the Back of the Eye Diseases of the back of the eye, such as: age-related wet macular degeneration, diabetic retinopathy and diabetic macular edema, are currently managed with injections of anti-vascular endothelial growth factor (anti-VEGF) drugs into the gel-like substance (the vitreous humor) that fills the eye between the lens and the retina. The currently used age-related wet macular degeneration injections are: Lucentis, which belongs …
Gene Therapy and Other Treatments That Work at the Genetic Level

Gene Therapy and Other Treatments That Work at the Genetic Level

Gene Therapy Stocks Experiencing Selloffs  Every investor in the biotech sector must have experienced selloffs of the stocks from companies specialized in gene therapy, gene editing, antisense, RNAi and mRNA therapies. Recently, bluebird bio’s (BLUE) stock was devastated. The selloffs occurred for many reasons, most of . . . This content is for paid subscribers. Please click here to subscribe or here to log in.
Unveiled Good News About Prohost Picked Biotech Stocks

Unveiled Good News About Prohost Picked Biotech Stocks

 The News Prohost Was Waiting for to Post Its Special Letter Prohost has one eye on the development-stage biotech and biopharmaceutical companies' scientific fundamentals and accomplishments as well as the financial results on the revenue-generating firms. Prohost has the second eye on the market performance, its volatility and the possible reasons it sinks every other day, or every other week, in calmer days during a …
Treating Hemoglobinopathies

Treating Hemoglobinopathies

Prohost Letter #433 Treating Hemoglobinopathies The most common genetic blood disorders are the hemoglobinopathies: sickle cell disease (SCD) and beta-thalassemia. Millions of people around the world are affected by these two conditions in which genetic defects impact the hemoglobin production.We called the past week “The Hemoglobinopathies’ Week”. Important and impacting news came with promising clinical trials data from two products aimed at treating sickle cell …